The Effect of Optic Flow Speed Manipulation and the Level of Immersion on the Gait Pattern in People Post-stroke

NCT ID: NCT04521829

Last Updated: 2022-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-10

Study Completion Date

2022-06-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the effect of manipulating the optic flow speed in the virtual environment on the gait pattern during virtual reality (VR) - enhanced treadmill walking in people post-stroke. Furthermore, the study will also investigate if the level of immersion has an effect on the rehabilitation outcomes by manipulating the optic flow speed in two different VR devices: the semi-immersive GRAIL system and the fully-immersive 'Oculus Rift S' HMD.

To properly understand the results of the people with a stroke, we will also investigate the effect of manipulating the optic flow speed and the level of immersion on the gait pattern in healthy people. That way, we can investigate whether virtual reality has a different influence on the gait pattern of people with a stroke than in healthy people.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

STUDY DESIGN

This study is an experimental, 2-group, multicenter trial in which people post-stroke and healthy people will perform 2 different sessions of treadmill walking. The 2 sessions will be carried out on 2 separate days within 10 days. Both sessions will be identical, only the VR system used to manipulate the optic flow speed will differ. The order of the 2 sessions and the optic flow speed manipulation will be randomized.

MATERIALS

GRAIL system: The Gait Real-time Interactive Lab (GRAIL) is an integrative motion capture system consisting of 10 optical motion cameras (Vicon Inc., Oxford, UK), a dual belt treadmill with integrated force plates, a 180-degree cylindrical projection screen system, and D-Flow software (Motekforce Link, Amsterdam, Netherlands). The treadmill of the GRAIL system has two modes: fixed walking speed or self-paced. For this study, the treadmill will be self-paced, meaning that the patient is in control and can choose the walking speed. The treadmill will follow the walking speed of the patient, which allow the patient to start, stop and change speed at will. The projection screen of the GRAIL system will assure a semi-immersive virtual environment. The GRAIL system is located in the Smart Space lab (UZ Gent) and will be made available at the researchers of the VUB/UZ Brussel.

Head-mounted display (HMD): The HMD VR system 'Oculus Rift S' (Oculus, LLS, US) is a low-cost HMD that fully integrates the user into the virtual environment by blocking out perception of the real-world. The "Oculus Rift S" will assure a fully immersive virtual environment. The researchers of the VUB/UZ Brussel have the HMD 'Oculus Rift S' in their possession and will make it available for the study.

PROCEDURE

Both sessions will be carried out in the Smart Space lab at the University Hospital of Ghent (Corneel Heymanslaan 10, 9000 Gent) where the GRAIL system is located.

Prior to the start of both sessions, some preparations will have to be done with regard to the outcome measures:

* Patients will be asked to fill in a questionnaire (the Simulator Sickness Questionnaire-Pre).
* Surface electrodes will be placed bilateral on the M. rectus femoris, M. vastus lateralis, M. biceps femoris, M. tibialis anterior, M. gastrocnemius medialis, M. deltoideus anterior part, M. deltoideus posterior part, M. latissimus dorsi. Electrode placement will follow the SENIAM guidelines. The skin underlying the electrode will be shaved and cleaned with alcohol to improve electrode-skin contact and reduce impedance.
* Reflective markers will be placed on fixed points of the lower and upper limbs of the patient. Marker placement will follow the Plug-in Gait full body model (VICON). For this model, the investigator will have to measure the following things in advance: body length, body weight, leg length, knee width, ankle width, shoulder offset, elbow width, wrist width, hand thickness.

After these preparations, patients will start to walk on the self-paced treadmill of the GRAIL system. For safety only, patients will walk with the safety harness. Patients will first be habituated to walking on the self-paced treadmill for 8 minutes without any form of VR. Patients need this habituation trial in order to get used to the self-paced treadmill system. After these 8 minutes, the treadmill will be stopped and patients will be seated for a 5-minute rest period. During the rest period, patients will be asked to fill in two short questionnaires (the Simulator Sickness Questionnaire-1, the VAS scales).

GRAIL session: After the 5-minute rest period, patients will walk for another 3 times 8 minutes with the VR. Patients are now walking while looking at a virtual environment that is projected onto the projection screen of the GRAIL device (semi-immersive). The optic flow will be different during each 8-minute walk. Between each walk, patients will rest for 5 minutes and during each rest period, patients will be asked to fill in a short questionnaire (the Simulator Sickness Questionnaire-2,-3).

HMD session: After the 5-minute rest period, patients will walk for another 3 times 8 minutes with the VR. Patients are now walking while wearing the HMD 'Oculus Rift' and are being fully immersed in a virtual environment (fully-immersive). The optic flow will be different during each 8-minute walk. Between each walk, patients will rest for 5 minutes and during each rest period, patients will be asked to fill in the a short questionnaire (the Simulator Sickness Questionnaire-2,-3).

To end both sessions, participants will be asked to fill in 3 questionnaires (the Simulator Sickness Questionnaire-Post, the VAS scales and the Igroup Presence Questionnaire).

RANDOMIZATION

First, the type of session will be randomized with 2 possible options: GRAIL - HMD or HMD - GRAIL. Second, the optic flow speed manipulation (matched, slow, fast) within the session will be randomized. The order of the manipulation will be the same in both sessions. The first 8 minutes in each session will always be the one without VR. Thereafter, the optic flow speed will be manipulated. There are 6 possible options for the randomization of the optic flow speed manipulation: matched - slow - fast / matched - fast - slow / slow - fast - matched / slow - matched - fast / fast - slow - matched / fast - matched - slow. The randomizations will be done through block randomization in Microsoft Excel®.

STUDY ANALYSIS

This study will investigate (1) the effect of manipulating the optic flow speed and (2) the effect of the level of immersion (semi-immersive GRAIL system with full-immersive HMD).

The effect optic flow speed has on the spatiotemporal gait parameters, kinematics, kinetics and muscle activity will be compared with walking without VR. In a first stage, the data will be visualized using LO(W)ESS smoothing (locally weighted scatterplot smoothing) to explore the observed effects over time (per condition and outcome), allowing for flexibility using this quasi-nonparametric approach. Next, relevant values expressing onset, magnitude and duration of the effect will be extracted:

* Onset: time point(s) at which the minimal clinically important difference (MCID) is exceeded. In case MCID is unknown, a 10% threshold will be used
* Magnitude: magnitude of the maximum (or maxima) and time point(s) at which the maximum is reached
* Duration: time between the onset and the time point at which the MCID (or 10% threshold) is no longer exceeded

These values will be compared between conditions in a two-way repeated measures ANOVA (optic flow speed \* device). If relevant (based on the exploratory analyses), additional in-depth statistics, such as functional data analysis, will be performed under the guidance of the Department of Statistics and Data Analysis of our university.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VR-enhanced treadmill walking

Participants will be tested during 2 sessions of VR-enhanced treadmill walking.

Group Type EXPERIMENTAL

Walking with different optic flow speeds with 2 different VR devices

Intervention Type OTHER

Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Walking with different optic flow speeds with 2 different VR devices

Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed with stroke (as defined by the World Health Organization)
* stroke onset ≥ 3 months
* ambulatory with an impaired gait pattern (FAC-score 2, 3 or 4)
* ability to walk on a treadmill for 4x8 minutes without bodyweight support
* adult (≥ 18 years)
* ability to signal pain, fear and discomfort
* ability to give informed consent


* ≥ 18 years of age
* normal or corrected-to-normal vision with glasses or contact lenses,
* no locomotion impairments

Exclusion Criteria

* other neurological deficits than stroke leading to impaired gait (e.g. Parkinson's disease, multiple sclerosis)
* comorbidities (e.g. COPD, severe osteoporosis, cardiovascular instability)
* visual and/or vestibular disorders that can interfere with the VR
* uncontrolled spasticity significantly interfering with the movement of the lower extremities (Modified Ashworth Scale \> 2)
* acute medical illness
* communicative/cognitive problems leading to the inability to understand and carry out instructions
* severe unilateral spatial neglect


* having a significant lower extremity injury during the last two years that might affect their gait
* having any type of vestibular/visual deficiency
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Ghent

OTHER

Sponsor Role collaborator

University Hospital, Ghent

OTHER

Sponsor Role collaborator

Vrije Universiteit Brussel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Emma De Keersmaecker

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eva Swinnen, Prof. Ph.D

Role: PRINCIPAL_INVESTIGATOR

Vrije Universiteit Brussel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Emma De Keersmaecker

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

References

Explore related publications, articles, or registry entries linked to this study.

De Keersmaecker E, Van Bladel A, Zaccardi S, Lefeber N, Rodriguez-Guerrero C, Kerckhofs E, Jansen B, Swinnen E. Virtual reality-enhanced walking in people post-stroke: effect of optic flow speed and level of immersion on the gait biomechanics. J Neuroeng Rehabil. 2023 Sep 25;20(1):124. doi: 10.1186/s12984-023-01254-0.

Reference Type DERIVED
PMID: 37749566 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VR study - GRAIL/HMD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.